Skip to main content

Reprexain and Alcohol/Food Interactions

There are 3 alcohol/food/lifestyle interactions with Reprexain (hydrocodone / ibuprofen).

Major

HYDROcodone food

Major Food Interaction

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including hydrocodone. Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills. In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.

GENERALLY AVOID: Consumption of alcohol while taking some sustained-release formulations of hydrocodone may cause rapid release of the drug, resulting in high systemic levels of hydrocodone that may be potentially lethal. Alcohol apparently can disrupt the release mechanism of some sustained-release formulations. In study subjects, the rate of absorption of hydrocodone from an extended-release formulation was found to be affected by coadministration with 40% alcohol in the fasted state, as demonstrated by an average 2.4-fold (up to 3.9-fold in one subject) increase in hydrocodone peak plasma concentration and a decrease in the time to peak concentration. Alcohol also increased the extent of absorption by an average of 1.2-fold (up to 1.7-fold in one subject).

GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of hydrocodone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of hydrocodone by certain compounds present in grapefruit. Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.

MANAGEMENT: Patients taking sustained-release formulations of hydrocodone should not consume alcohol or use medications that contain alcohol. In general, potent narcotics such as hydrocodone should not be combined with alcohol. Patients should also avoid consumption of grapefruit or grapefruit juice during treatment with hydrocodone.

References

  1. "Product Information. Zohydro ER (hydrocodone)." Zogenix, Inc (2013):
Major

High Blood Pressure (Hypertension)

Major Potential Hazard, Moderate plausibility

NSAIDs - fluid retention

Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs). Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure. Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.

References

  1. "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn PROD (2002):
  2. "Product Information. Nalfon (fenoprofen)." Xspire Pharma PROD (2002):
  3. "Product Information. Indocin (indomethacin)." Merck & Co., Inc PROD (2002):
  4. "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories PROD (2002):
  5. "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc PROD (2002):
  6. "Product Information. Anaprox (naproxen)." Roche Laboratories PROD (2006):
  7. "Product Information. Clinoril (sulindac)." Merck & Co., Inc PROD (2001):
  8. "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical PROD (2001):
  9. "Product Information. Relafen (nabumetone)." SmithKline Beecham PROD (2001):
  10. "Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals PROD (2001):
  11. "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn PROD (2001):
  12. "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories PROD (2001):
  13. "Product Information. Daypro (oxaprozin)." Searle PROD (2001):
  14. "Product Information. Mobic (meloxicam)." Boehringer-Ingelheim PROD (2001):
View all 14 references
Moderate

High Blood Pressure (Hypertension)

Moderate Potential Hazard, Moderate plausibility

NSAIDs - hypertension

Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events. NSAIDs should be used with caution in patients with hypertension. Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.

References

  1. "Product Information. Indocin (indomethacin)." Merck & Co., Inc PROD (2002):
  2. "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc PROD (2002):
  3. "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals PROD (2001):
  4. "Product Information. Relafen (nabumetone)." SmithKline Beecham PROD (2001):
  5. "Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals PROD (2001):
  6. "Product Information. Dolobid (diflunisal)." Merck & Co., Inc PROD (2001):
  7. "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn PROD (2001):
  8. "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories PROD (2001):
  9. "Product Information. Daypro (oxaprozin)." Searle PROD (2001):
  10. "Product Information. Celebrex (celecoxib)." Searle PROD (2001):
  11. "Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc (2012):
  12. "Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD) (2016):
View all 12 references

Reprexain drug interactions

There are 828 drug interactions with Reprexain (hydrocodone / ibuprofen).

Reprexain disease interactions

There are 29 disease interactions with Reprexain (hydrocodone / ibuprofen) which include:


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.